PROGRAM: WEDNESDAY, MAY 24, 2006

8:00AM-9:00AM

CONTRIBUTED PODIUM PRESENTATIONS - SESSION III

Health Expenditures - Salon A

HE1
ECONOMIC EVALUATION OF A 90-DAY RETAIL PRESCRIPTION DRUG PROGRAM IN A PHARMACY BENEFIT MANAGEMENT SETTING
Sun SX, Jiang JZ, Lee KY
Walgreens Health Services, Deerfield, IL, USA

HE2
ESTIMATING OUT-OF-POCKET PHARMACEUTICAL EXPENDITURES UNDER THE NEW MEDICARE DRUG LAW FOR PATIENTS WITH MENTAL DISORDERS – AN ANALYSIS OF CLAIMS DATA FROM RETIREE MEDICAL PLANS
Gibson TB1, Ozminkowski RJ1, Mark T2, Costa L3
1Thomson Medstat, Ann Arbor, MI, USA, 2Thomson Medstat, Washington, DC, USA, 3Research Data Solutions, Boston, MA, USA

HE3
DIFFERENTIAL RACIAL AND ETHNIC DISPARITIES IN HEALTH EXPENDITURE AND SELF-PERCEIVED HEALTH STATUS IN THE UNITED STATES
Wang J1, Mullins CD2, Zuckerman IH2, White-Means SI1, Arreola R1, Hufstader MA1, Hutchison L1, Walker GD1
1University of Tennessee, Memphis, TN, USA, 2University of Maryland Baltimore, Baltimore, MD, USA

HE4
RACIAL/ETHNIC DISPARITIES IN LENGTH OF STAY AND COST OF INPATIENT CARE FOR INTRACEREBRAL HEMORRHAGE: EVIDENCE FROM THE HEALTHCARE COST AND UTILIZATION PROJECT DATABASE
Russell MW1, Boulanger L1, Joshi AV2, Neumann PJ3, Menzin J1
1Boston Health Economics, Inc, Waltham, MA, USA, 2Novo Nordisk Inc, Princeton, NJ, USA, 3Tufts-New England Medical Center, Boston, MA, USA

High Impact - Salon B

HI1
ADULT ECONOMIC STATUS AND OBESITY IN THE UNITED STATES: 2000 - 2002
Wu E1, Xie J1, Crémieux PY1, Sullivan PW2
1Analysis Group, Inc, Boston, MA, USA, 2University of Colorado Health Sciences Center, Denver, CO, USA

HI2
CLINICAL IMPACT OF PHARMACOTHERAPY VERSUS NON-PHARMACOLOGIC MANAGEMENT AMONG COMMERCIALLY INSURED PERSONS AGED ³65 YEARS WITH OVERACTIVE BLADDER
Joyce AT1, Jumadilova Z2, Trocio J2, Foltz Boklage S3, Girase P1
1PharMetrics, a unit of IMS, Watertown, MA, USA, 2Pfizer, Inc, New York, NY, USA, 3PharMetrics, a unit of IMS, Fort Washington, PA, USA

HI3
THE EFFECTS OF STATIN (HMG-COA REDUCTASE INHIBITOR) COPAYMENTS AND STATIN ADHERENCE ON MEDICAL CARE OUTCOMES AND EXPENDITURES
Gibson TB1, Mark T2, Axelsen K3, Mackell J4, King H3, Baser O1, McGuigan K3
1Thomson Medstat, Ann Arbor, MI, USA, 2Thomson, Washington, DC, USA, 3Pfizer Global Pharmaceuticals, New York, NY, USA, 4Pfizer, Inc, New York, NY, USA

HI4
IMPACT OF PATIENT SELECTION CRITERIA AND MODEL SPECIFICATION ON COMPARISONS OF ALTERNATIVE THERAPIES: THE CASE OF ATYPICAL ANTIPSYCHOTICS
Marshall TS, McCombs JS
University of Southern California, Los Angeles, CA, USA

Mental Health - Salon C

MH1
NATIONAL TRENDS IN THE DIAGNOSIS OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER AND USE OF STIMULANTS AMONG CHILDREN IN THE UNITED STATES, 1993-2003
Toh S
Harvard School of Public Health, Boston, MA, USA

MH2
USE PATTERNS AND OUTCOMES ASSOCIATED WITH TYPICAL DEPOT ANTIPSYCHOTIC AGENTS IN THE SCHIZOPHRENIA CARE ASSESSMENT PROGRAM (SCAP) – AUSTRALIA
Christova L1, Mudge M1, Davey P1, Montgomery W2
1M-TAG Pty Ltd - A unit of IMS Health, Sydney, NSW, Australia, 2Eli Lilly and Company, Sydney, NSW, Australia

MH3
NICE'S COST-EFFECTIVENESS APPRAISAL OF CHOLINESTERASE INHIBITORS: ASKING THE RIGHT QUESTION
Getsios D1, Caro JJ2, Kavanagh S3
1Caro Research Institute, Hammonds Plains, NS, Canada, 2Caro Research Institute, Concord, MA, USA, 3Janssen Pharmaceutica N.V, Beerse, Beerse, Belgium

MH4
MEDICAL COSTS AND HOSPTALIZATION OF ADULTS DIAGNOSED WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER WHO RECEIVED ALTERNATIVE THERAPIES
Wu E1, Birnbaum H1, Zhang H2, Radeva J1, Yang E1, Castor A1
1Analysis Group, Inc, Boston, MA, USA, 2McNeil Consumer & Specialty Pharmaceuticals, Fort Washington, PA, USA

Urological/Renal - Salon D

UR1
THE ECONOMIC IMPACT OF EPOETIN ALFA (EPO) THERAPY ON DELAYING TIME TO DIALYSIS IN ELDERLY PATIENTS WITH CHRONIC KIDNEY DISEASE (CKD)
Lefebvre P1, Duh M2, Mody S3, Bookhart B3, Piech CT3
1Groupe d'Analyse, Ltée, Montréal, QC, Canada, 2Analysis Group, Inc, Boston, MA, USA, 3Ortho Biotech Clinical Affairs, LLC, Bridgewater, NJ, USA

UR2
ECONOMIC BURDEN OF UNTREATED ANEMIA IN PRE-DIALYSIS CHRONIC KIDNEY DISEASE (PCKD) PATIENTS: AN EMPLOYER'S PERSPECTIVE
Moyneur É1, Bookhart B2, Mody S2, Fournier AA1, Mallet D3, Duh M4
1Groupe d'Analyse, Inc, Montréal, QC, Canada, 2Ortho Biotech Clinical Affairs, LLC, Bridgewater, NJ, USA, 3Ingenix Employer Solutions, New Haven, CT, USA, 4Analysis Group, Inc, Boston, MA, USA

UR3
FACTORS ASSOCIATED WITH CARE SEEKING FOR OVERACTIVE BLADDER SYMPTOMS
Nichol MB1, Brubaker L2, Fanning K3, Hussein M4, Becker RV4, Benner JS4
1University of Southern California, Los Angeles, CA, USA, 2Loyola University Medical Center, Maywood, IL, USA, 3Vendanta Associates Inc, Wilmington, NC, USA, 4ValueMedics Research, LLC, Falls Church, VA, USA

UR4
THE COST-EFFECTIVENESS OF VARIOUS TREATMENT STRATEGIES FOR ABNORMAL UTERINE BLEEDING
Trussell J1, Liu Z2, Guo A3, Doan QV2, Dubois RW2, Borenstein J4, Singh RH5, Blumenthal PD5
1Princeton University, Princeton, NJ, USA, 2Cerner Health Insights, Beverly Hills, CA, USA, 3Berlex Laboratories, Montville, NJ, USA, 4UCLA, Los Angeles, CA, USA, 5Johns Hopkins University, Baltimore, MD, USA

9:00AM-9:15AM

BREAK

9:15AM-10:15AM

CONTRIBUTED PODIUM PRESENTATIONS - SESSION IV

Cancer- Salon A

CN1
ECONOMIC OUTCOMES IN HEPATOCELLULAR CARCINOMA AND METASTATIC LIVER DISEASE PATIENTS: A PRIVATE PAYER PERSPECTIVE
Pelletier EM1, Dembek CJ1, Gazelle GS2
1Boston Scientific Corporation, Natick, MA, USA, 2Massachusetts General Hospital, Boston, MA, USA

CN2
MAMMOGRAPHY SCREENING USE AMONG MEDICARE BENEFICIARIES AGE 65 OR OLDER
Zuckerman IH1, Du D1, Royak-Schaler R1, Wang J2
1University of Maryland Baltimore, Baltimore, MD, USA, 2University of Tennessee College of Pharmacy, Memphis, TN, USA

CN3
COLONOSCOPY PROCEDURE RATES AMONG PRIVATE-PAY PATIENTS INCREASED SUBSTANTIALLY BETWEEN 2000 AND 2004
Amorosi SL, Lacey MJ
Boston Scientific, Natick, MA, USA

CN4
COMPARISON OF EPOETIN ALFA AND DARBEPOETIN ALFA TREATMENT COSTS IN AN INPATIENT ONCOLOGY SETTING
Duh M1, Vekeman F2, Mckenzie RS3, Lefebvre P2, Watson S3, Mody S3, Piech CT3
1Analysis Group, Inc, Boston, MA, USA, 2Groupe d'Analyse, Ltée, Montréal, QC, Canada, 3Ortho Biotech Clinical Affairs, LLC, Bridgewater, NJ, USA

Cardiovascular - Salon B

CV1
INCREMENTAL EXPENDITURE OF TREATING HYPERTENSION IN THE UNITED STATES
Balu S1, Thomas J2
1Abt Associates Inc, Lexington, MA, USA, 2Purdue University, West Lafayette, IN, USA

CV2
IMPACT OF VENTRICULAR ARRHYTHMIA ON MORTALITY, HEALTH CARE UTILIZATION AND COST IN HOSPITALIZED ACUTE MYOCARDIAL INFARCTION PATIENTS
Wang F1, Iyer S2, Ciuryla V2, Feng_Wang P3
1Cephalon, Inc, Fraser, PA, USA, 2Wyeth Research, Collegeville, PA, USA, 3Premier Healthcare Informatics, Charlotte, NC, USA

CV3
SWITCHING, AUGMENTATION AND TITRATION OF LIPID LOWERING AGENTS OF MEDICARE/MEDICAID DUAL ELIGIBLE PATIENTS BY ETHNICITY
Mucha L1, Mark T2, Axelsen K3
1Thomson Medstat, Cambridge, MA, USA, 2Thomson, Washington, DC, USA, 3Pfizer Global Pharmaceuticals, New York, NY, USA

CV4
MANAGING CONGESTIVE HEART FAILURE: COHORT ANALYSIS OF USE AND COST OF HOSPITAL, EMERGENCY DEPARTMENT AND OBSERVATION UNIT CARE OVER TWELVE MONTHS
O'Brien JA, Duran PA, Pitoniak-Morse C, Caro JJ
Caro Research Institute, Concord, MA, USA

Infectious Disease - Salon C

ID1
“GATEKEEPERS AND SENTINELS”: IMPLICATIONS FOR DRUG UTILIZATION POLICY IN THE COMMUNITY SETTING
Kahan NR1, Waitman DA1, Kahan E2, Chinitz DP3
1Leumit Health Fund, Tel-Aviv, Israel, 2Sackler Faculty of Medicine, Tel-Aviv University, Kfar Saba, Israel, 3The Hebrew University of Jerusalem School of Public Health, Jerusalem, Israel

ID2
OUTCOMES ASSOCIATED WITH ANTIFUNGAL DRUG SWITCHING IN PATIENTS WITH SERIOUS CANDIDA INFECTIONS
He J, Wang C, Griffin B, Smith J, Mahoney A, Burleigh E
Solucient, Berkerley Heights, NJ, USA

ID3
TRENDS IN HIV TREATMENT EXPERIENCE AND OUTCOMES AS OBSERVED IN A SAMPLE OF PATIENTS FROM A US CLINICAL DATABASE
Martin SC, Stellhorn R, Nuyts G
Johnson & Johnson Pharmaceutical Services, LLC, Raritan, NJ, USA .

ID4
COMPLIANCE WITH ANTIBIOTIC TREATMENT GUIDELINES IN MEDICARE MANAGED CARE PATIENTS WITH COMMUNITY-ACQUIRED PNEUMONIA (CAP) IN AMBULATORY SETTINGS
Wu JH1, Howard DH2, McGowan JE2, Turpin RS1, Hu XH1
1Merck & Co., Inc, West Point, PA, USA, 2Rollins School of Public Health of Emory University, Atlanta, GA, USA

Neurological Disorders - Salon D

ND1
THE INDIRECT COST BURDEN OF MIGRAINE AMONG SEVERAL LARGE U.S. EMPLOYERS
Hawkins K1, Rupnow M2, Wang S3
1Thomson-Medstat, Ann Arbor, MI, USA, 2Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville, NJ, USA, 3Thomson-Medstat, Cambridge, MA, USA

ND2
EVALUATIONS OF THE PRESCRIBED DAILY DOSES OF TRANSDERMAL FENTANYL AND TRANSDERMAL BUPRENORPHINE IN CANCER AND NON-CANCER PATIENTS IN GERMANY: RESULTS FROM A RETROSPECTIVE DATABASE ANALYSIS
Haerdtl G1, Niemann U1, Nuijten MC2, Poulsen Nautrup B3
1MAIX Market Research & Consulting, Aachen, Germany, 2Erasmus University Rotterdam, Rotterdam, Netherlands, 3Gruenenthal GmbH, Aachen, Germany

ND3
A DESCRIPTION OF OFFICE VISIT RATES AND PRESCRIPTION USE FOR INSOMNIA AMONG RECIPIENTS OF A STATE MEDICAID PROGRAM
Roy AN, Smith MJ
West Virginia University, Morgantown, WV, USA

ND4
IMPACT OF TOPIRAMATE FOR MIGRAINE PROPHYLAXIS ON WORKPLACE PRODUCTIVITY: RESULTS FROM TWO U.S. RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIALS
Gagne JJ1, Lofland JH1, Rupnow M2, Smith KD1, Poston S1, Pizzi LT1
1Thomas Jefferson University, Philadelphia, PA, USA, 2Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville, NJ, USA

10:15AM-10:45AM

BREAK - Salon A-D Foyer

Coffee sponsored by Forest Laboratories

10:45AM-11:15AM

ISPOR RESEARCH CONTRIBUTED AWARDS PRESENTATION - Salon E & F

C. Daniel Mullins PhD, Chair ISPOR Awards Committee and Assistant Professor, University of Maryland, School of Pharmacy, Baltimore, MD, USA

ISPOR Best Contributed Poster Presentation
Overview by: Benjamin M. Craig, PhD, ISPOR Contributed Poster Awards Task Force Chair and Assistant Professor, The University of Arizona School of Pharmacy, Tucson, AZ, USA

ISPOR Best Contributed Podium Presentation
Overview by: David A, Holdford PhD, Virginia Commonwealth University, Richmond, VA, USA

11:15AM-12:30PM

THIRD PLENARY SESSION - Salon E & F

THE PATIENT VOICE IN MEDICAL PRODUCT EVALUATION: FDA DRAFT GUIDANCE ON MEASURING PATIENT-REPORTED OUTCOMES

During this session, the FDA Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical
Product Development to Support Labeling Claims' will be debated. The pharmaceutical industry perspective,
ISPOR membership concerns, and a response by the FDA as well as an example of a cooperative solution for patient-reported outcomes measures in medical product development will be presented.

Moderator: Donald Patrick PhD, MSPH, Professor, University of Washington, Seattle, WA, USA

Speaker: Laurie Burke MPH, RPh, Director, Study Endpoints and Label Dev., Office of New Drugs, CDER, FDA, Silver Spring, MD, USA

Industry Perspective
Speaker: Margaret Rothman PhD, Executive Director, Johnson & Johnson Pharmaceutical Research, Raritan, NJ, USA

Comments from ISPOR
Speaker: Patrick Marquis, MBA, MD, Managing Director, Mapi Values, Boston, MA, USA and Chair, ISPOR PRO / QOL Information in Regulatory & Health care Decisions Working Group of the PRO SIG, USA

Cooperative Solutions
Speaker: Nancy Kline Leidy PhD, President, Health Care Analytics Group, United BioSource Corporation, Bethesda, MD, USA